Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03821233 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
A Phase 1 study, sponsored by Zymeworks BC.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT03821233 is a Phase 1 study that has completed, run by Zymeworks BC. The registered enrollment target is 112 participants.
The verdict
NCT03821233, a Phase 1 study, has completed, sponsored by Zymeworks BC.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.
Interventions
- DRUG ZW49
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03821233
The ClinicalTrials.gov registry entry for NCT03821233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zymeworks BC, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZW49 is the first listed.
NCT03821233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03821233 about?
NCT03821233 is a clinical study titled "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers". This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally a...
What is the current status of trial NCT03821233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2019-04-15. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT03821233?
The interventions under investigation include: ZW49 (DRUG).
Who is sponsoring clinical trial NCT03821233?
This trial is sponsored by Zymeworks BC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.